44 results about "Abcg2" patented technology

The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.

The present invention relates to a method of isolating hematopoietic stem cells from adipose tissue. The method yields a notably high number of CD34⁺, ALDH^br and/or ABCG2-expressing cells, comprising hematopoietic stem cells, permitting the use of the cells with no or minimal expansion.

The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.

The present invention provides pyrazolo[1,5-a]pyrimidine compounds which inhibit cancer-associated transporter proteins, methods of treating or preventing the onset of a cancer-associated transporter protein-mediated disease by administering such compounds, and pharmaceutical compositions comprising such compounds. In one embodiment, the invention provides pyrazolo[1,5-a]pyrimidine efflux inhibitors that are selective toward ABCG2 over ABCB1. Compounds and compositions according to the present invention may be used to treat cancer, including drug resistant (DR) and multiple drug resistant (MDR) cancers.

The invention relates to the multi-drug resistance (MDR) of Lapatinib (formula 1) in reversing tumour cells which are mediated by membrane transport proteins (ABC) families such as P-glycoprotein (P-gp), multi-drug resistance related protein (MRP1), breast cancer multi-drug resistance related proteins (ABCG2 and BCRP) and the like. The Lapatinib is used together with anti-cancer drugs such as anthracyclines, catharanthines, taxols, podophyllotoxins, camptothecins and the like to restore the sensitivity of MDR tumor cells to the anticancer drugs. The Lapatinib is applied to combination chemotherapy of drug-resistant patients in clinical chemotherapy or the prevention of drug-resistance generation for the tumor cells.

The invention relates to a detection of four sites of single nucleotide polymorphism (SNP) which are arranged on two human body xenobiotics metabolismenzyme genes including ABCG2 and CYP2E1 and which are associated with the systemic lupus erythematosus (SLE). The invention also can use four sites of single nucleotide polymorphism (SNP) to forecast the liability of systemic lupus erythematosus and to determine the drug to cure the systemic lupus erythematosus. The information provided by the invention is helpful for preventing systemic lupus erythematosus (SLE) and for developing effective new treatments.

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R¹, R², R³, X¹, X², X³, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.

The invention relates to a method and kit for detecting human arthrolithiasis-related gene mutation sites. The detection method comprises the following steps: (1) designing specific primers aiming atABCG2 and SLC2A9 genes; (2) performing specific polymerase chain reaction (PCR) amplification so as to obtain target fragments containing ABCG2 and SLC2A9 genes; (3) performing restrictive enzyme disgestion on PCR product fragments; (4) performing single base extension; (5) performing desalting purification treatment; and (6) then detecting and analyzing sequences of target genes ABCG2 and SLC2A9genes by use of a nucleic acid velocitron. The method for detecting the human arthrolithiasis-related gene mutation sites is high in detection accuracy, high in experiment repeatability, great in fluxand low in cost. The invention also provides a kit for for detecting human arthrolithiasis-related gene mutation sites. The kit comprises a specific primer pair for amplifying ABCG2 and SLC2A9 genes.The kit for for detecting human arthrolithiasis-related gene mutation sites is capable of simplifying experimental procedures and has the advantages of short manual operation time, low difficulty andhigh experiment automation degree.

The invention discloses a primer combination for guiding related gene detection of individualized medications of a risuvastatin drug. The primer combination is characterized by including specific primers and probes for an ABCG2(rs2231142) gene locus and an SLCO1B1(rs4149056) gene locus. The invention further discloses a kit containing the primer combination and an analytical method of the kit. According to the primer combination, the characteristics of easy operation, the economical efficiency, rapid detection, the high accuracy, the good specificity and easy result interpretation are achieved, the polymorphism of related genes of the individualized medications of the risuvastatin drug is rapidly and accurately measured to lower the adverse reaction of common medications of the rosuvastatin drug in clinic, the medical cost is lowered, and social resources are saved.

To specify a molecule associated with the onset of gout so as to provide a method for evaluating a diathesis of uric acid-related diseases and a diathesis of inflammation-related diseases, an evaluation kit for carrying out the method, an inspection object, and a drug, on the basis of the molecule specified above, for contributing to the early treatment and prevention of the uric acid-related diseases and inflammation-related diseases. The molecule includes any one protein and cDNA of CNIH2-PACS1, ALDH2, MYL2-CUX2, GCKR, MAP3K11, NPT4, ABCG2, HIST1H2BF/HIST1H4E, HIST1H2BE/HIST1H4D and FAM35A, or proteins of combination thereof with GLUT9, NPT1, URAT1, or NXRN2, and is capable of selectively inducing gout. A molecule includes protein and cDNA of an ABCG2 variant and is capable of selectively and ATP-dependently decreasing urate excretion.

Disclosed is a method of producing ABCG2-positive corneal limbal stem cells through inducing pluripotent stem cells first into eye precursor cells and then differentiating the eye precursor cells into ABCG2-positive corneal limbal stem cells. Also disclosed is a method of maintaining ABCG2-positive phenotype of corneal limbal stem cells, such as primary corneal limbal stem cells.

The invention provides application of tea polypeptides in restoring mutation expression of ABCG2 Q141K to improve gout caused by AGCG2 Q141K mutation. The technique herein belongs to the field of teahealth and functionality; the invention particularly relates to researches on the health functions of tea active ingredients.